Vanda Pharmaceuticals (VNDA) Trading Up 7.6%

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares were up 7.6% during trading on Friday . The company traded as high as $20.05 and last traded at $19.90. Approximately 1,062,150 shares changed hands during mid-day trading, an increase of 81% from the average daily volume of 587,604 shares. The stock had previously closed at $18.50.

VNDA has been the subject of a number of analyst reports. Zacks Investment Research raised Vanda Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $23.00 price objective for the company in a research report on Sunday, July 15th. Cantor Fitzgerald initiated coverage on Vanda Pharmaceuticals in a research report on Wednesday, August 22nd. They set a “neutral” rating and a $26.00 price objective for the company. Citigroup initiated coverage on Vanda Pharmaceuticals in a research report on Wednesday, May 23rd. They set a “buy” rating and a $26.00 price objective for the company. Seaport Global Securities reaffirmed a “buy” rating and set a $26.00 price objective on shares of Vanda Pharmaceuticals in a research report on Thursday, August 2nd. Finally, Stifel Nicolaus initiated coverage on Vanda Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $30.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $25.50.

The firm has a market capitalization of $966.40 million, a P/E ratio of -56.86 and a beta of 0.52.



Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, August 1st. The biopharmaceutical company reported $0.09 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.14. The business had revenue of $47.40 million during the quarter, compared to analyst estimates of $47.28 million. Vanda Pharmaceuticals had a return on equity of 0.68% and a net margin of 0.73%. The company’s quarterly revenue was up 12.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.03 EPS. research analysts anticipate that Vanda Pharmaceuticals Inc. will post -0.01 EPS for the current year.

Several institutional investors have recently bought and sold shares of VNDA. venBio Select Advisor LLC increased its holdings in shares of Vanda Pharmaceuticals by 97.0% in the 1st quarter. venBio Select Advisor LLC now owns 2,775,191 shares of the biopharmaceutical company’s stock worth $46,762,000 after purchasing an additional 1,366,245 shares in the last quarter. First Manhattan Co. increased its holdings in shares of Vanda Pharmaceuticals by 478,333.0% in the 2nd quarter. First Manhattan Co. now owns 956,866 shares of the biopharmaceutical company’s stock worth $18,228,000 after purchasing an additional 956,666 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Vanda Pharmaceuticals by 16.3% in the 2nd quarter. BlackRock Inc. now owns 4,960,924 shares of the biopharmaceutical company’s stock worth $94,506,000 after purchasing an additional 693,922 shares in the last quarter. Macquarie Group Ltd. increased its holdings in shares of Vanda Pharmaceuticals by 12.1% in the 2nd quarter. Macquarie Group Ltd. now owns 2,555,004 shares of the biopharmaceutical company’s stock worth $48,673,000 after purchasing an additional 276,057 shares in the last quarter. Finally, Hawk Ridge Capital Management LP purchased a new position in shares of Vanda Pharmaceuticals in the 1st quarter worth $4,362,000. 93.56% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Further Reading: How to Calculate Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply